NEW YORK (GenomeWeb) – Geneseq Biosciences and Australian Clinical Labs today announced a partnership to commercialize a noninvasive melanoma test.
The partners will offer the blood-based test, called Melaseq, which was developed by Geneseq for detecting melanoma signatures. Tissue samples can also be used for Melaseq, they said. Â
The test measures 38 circulating microRNAs that regulate processes that melanoma cells undergo as they become malignant, according to Geneseq's website. They include three markers of angiogenesis and inflammation; 11 markers of immune processes and drug resistance; eight markers associated with tumor growth; and 16 markers associated with invasion and metastasis.
The test, which can be used for diagnostic and monitoring purposes, was developed using NanoString's technology.
"This agreement gives us access to a world-class clinical and biospecimen network, in addition to the reimbursement, regulatory, and commercial expertise necessary to make Melaseq a success," said Geneseq CEO Ryan Van Laar in a statement.
Financial and other terms of the agreement were not disclosed.
Based in Melbourne, Australia, Geneseq was founded in 2016 and develops liquid biopsy tests. Australian Clinical Labs provides pathology services to public hospitals throughout Australia.